EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436

Maryana Teufelsbauer, Sandra Stickler, Marie-Therese Eggerstorfer, Dennis Clyde Hammond, Gerhard Hamilton

Breast Cancer Research and Treatment · 2024-11 · 208 (1) · 89-101

DOI: 10.1007/s10549-024-07403-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 19.06.2024. Verfasst von Maryana Teufelsbauer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinics of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cell Proliferation, Cell Movement. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific Fund of the Mayor of the City of Vienna, Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to find whether the proliferation and migration of triple negative breast cancer (TNBC) cell lines can be reduced by treatment with bromodomain and extra-terminal domain (BET) inhibitor JQ1 and BET protein targeting chimeras (PROTACs) ARV-771 and MZ1.

Methods

Cytotoxicity tests, scratch migration assays and western blot proteome profiler arrays for protein expression of cancer-related proteins were used to evaluate the impact of a BET-inhibitor and two BET-directed PROTACs on cell viability, migration and on protein expression.

Results

JQ1 and the PROTACs MZ1 and ARV-771 significantly inhibited the growth and migration of the KRAS G13D-mutated MDA-MB-231 cells. In this cell line, the PROTACs suppressed the residual expression of ERBB2/HER2, 3 and 4 that are essential for the proliferation of breast cancer cells and this cell line proved sensitive to HER2 inhibitors. In contrast, the effects of the PROTACs on the protein expression of MDA-MB-436 cells mostly affected cytokines and their cognate receptors.

Conclusion

The degradation of BET-protein by PROTACs demonstrated significant anti-proliferative effects. The KRAS-mutated MDA-MB-231 cells belong to the low-HER2 expressing tumors that have a poorer prognosis compared to HER2-null patients. Since first oral PROTACs against tumor hormone receptors are in clinical trials, this mode of tumor therapy is expected to become an important therapeutic strategy in the future treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCell ProliferationCell MovementHumansCell Line, TumorFemaleTriazolesAzepinesCell SurvivalErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsGene Expression Regulation, NeoplasticProteolysis Targeting ChimeraBromodomain Containing ProteinsProteins

Stichwörter der Autor:innen

ARV-771BETHER2MZ1PROTACTriple negative breast cancer

Substanzen

TriazolesAzepinesErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsProteolysis Targeting ChimeraBromodomain Containing ProteinsProteinsbromodomain and extra-terminal domain protein, human(+)-JQ1 compoundERBB2 protein, human

Autor:innen und Institutionen

  • Clinics of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria.
  • Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Center for Breast and Body Contouring, Grand Rapids, MI, 49546, USA.
  • Institute of Pharmacology, Medical University of Vienna, Vienna, Austria. gerhard.hamilton@meduniwien.ac.at.

Förderung

  • Medical Scientific Fund of the Mayor of the City of Vienna
  • Medical University of Vienna

Zitieren

APA

Teufelsbauer, M., Stickler, S., Eggerstorfer, M. T., Hammond, D. C., & Hamilton, G. (2024). BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Research and Treatment, 208(1), 89-101. https://doi.org/10.1007/s10549-024-07403-w

Vancouver

Teufelsbauer M, Stickler S, Eggerstorfer MT, Hammond DC, Hamilton G. BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Research and Treatment. 2024;208(1):89-101. doi:10.1007/s10549-024-07403-w

BibTeX
@article{Teufelsbauer2024,
  author = {Teufelsbauer, Maryana and Stickler, Sandra and Eggerstorfer, Marie-Therese and Hammond, Dennis Clyde and Hamilton, Gerhard},
  title = {BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  volume = {208},
  number = {1},
  pages = {89--101},
  doi = {10.1007/s10549-024-07403-w}
}
Kostenlos starten →